Patients with ulcerative colitis who discontinue 5-aminosalicylate therapy once they begin anti-TNF therapy do not appear at great risk for adverse clinical events, according to research published in Gut. Researchers analyzed data from 3,589 patients with UC taken from two national cohorts: the United States Truven MarketScan health claims database and the Danish health registers. They included patients who started taking anti-TNF after having been on 5-ASAs for at least 90 days and grouped them based on whether they discontinued 5-ASA therapy. Of 2,890 patients in the U.S. cohort, 1,951 continued 5-ASA and 939 stopped. In Denmark, 474 continued and 225 withdrew.

Read More